The significant decrease in GLT-1 levels observed in the nucleus accumbens of rats that had consumed morphine for fifty-six days was completely reversed by the co-administration of NAC (40 mg/kg/day, i.p.) and ibudilast (7.5 mg/kg/day, i.p.). by María Elena Quintanilla (8068691)

NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day). by Xueqin lu (22250795)

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

Subjects:

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

The parameters of gas exchange markedly decreased in maize <i>zmstomagen1/2</i> mutant compared with in wild type (WT). by Juan-Juan Xu (18590868)

Lifespan of a single <i>T. utriculata</i> rosette. by Alexandra M. Campbell (3284094)

<i>Tillandsia utriculata</i> death rate data by size class. by Alexandra M. Campbell (3284094)

Variables for the bromeliad agent representing a single <i>T. utriculata</i> rosette. by Alexandra M. Campbell (3284094)

Distribution of population at final time (left) and change in mean MSI at final time (right) from simulations across 1000 parameter sets when weevils are absent (red) and with weev... by Alexandra M. Campbell (3284094)

Histograms of (A) distance measured in meters to nearest neighboring tree given bin widths of 2 m (<i>n</i> = 44), and (B) basal areas of all sampled trees (<i>n</i> = 58; bin widt... by Alexandra M. Campbell (3284094)

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline T-cell activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects: